A to Z / Growth hormone
GHRP-2
Also known as Pralmorelin, growth hormone releasing peptide-2, KP-102.
Best known for The older growth hormone secretagogue that raises cortisol
Evidence★★☆☆☆
Safety dataPoorly characterised
Route Injectable (subcutaneous)
United StatesNot approved
AustraliaSchedule 4 + Appendix D cl.5 (listed as Pralmorelin)
as at 16 September 2026
What it is
GHRP-2 (pralmorelin) is a synthetic growth hormone secretagogue acting on the ghrelin receptor. It predates ipamorelin and is approved in Japan as a diagnostic agent for assessing growth hormone deficiency. It is not approved in the United States.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with GHRP-6, Ipamorelin, Hexarelin, CJC-1295 (with DAC)
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about GHRP-2. It is not medical advice and not a recommendation to use it.